Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Conclusions: The authors concluded that an immunemediated demyelinating polyneuropathy is a well-recognized entity in diabetic patients, and for those with the clinical and EP features and significant functional deficits, immunomodulating therapy should be considered.
Editors comments
Although not strictly a clinical trial, I elected to include this paper to raise awareness among endocrinologists that within the collective condition known as diabetic somatic polyneuropathy, there may be a minority of patients who may benefit from specific treatments. CIDP should be suspected in neuropathic diabetic patients if 1) there is a prominence of motor symptoms and signs involving distal or proximal lower limb muscles or upper limbs; 2) after some years of a predominant sensory neuropathy, a motor neuropathy develops with progressive symptoms or signs; or 3) patients are diagnosed with amyotrophy (proximal motor neuropathy). However, the diagnosis should not be made on clinical grounds alone: there are characteristic EP criteria and some patients may require examination of nerve histology or cerebrospinal fluid [1,3,4]. Referral to a neurologist with an interest in peripheral nerve disorders is indicated together with a detailed EP examination. The reason to consider a diagnosis of CIDP in neuropathic diabetic patients with these atypical features is becoming increasingly clear: a response to specific immunomodulatory therapy (usually intravenous immunoglobulin) may, in some cases, be dramatic in terms of clinical improvement [2,5]. There is now an urgent need for good qualitycontrolled clinical trials of immunosuppressive agents in CIDP [6], especially in diabetic patients.
References
1. 2. Sharma KR, Cross J, Farronay O, et al.: Demyelinating neuropathy in diabetes mellitus. Arch Neurol 2002, 59:758765. Sharma KR, Cross J, Ayyar DR, et al.: Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy. Arch Neurol 2002, 59:751757.
438
Microvascular ComplicationsNeuropathy
3.
4.
Nicolas G, Maisonobe T, Le Forestier N, et al.: Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2002, 25:2630. Rotta FT, Sussman AT, Bradley WG, et al.: The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2000, 173:129139.
5.
6.
Cocito D, Ciaramitaro P, Isoardo G, et al.: Intravenous immunoglobulin as first treatment in diabetics with concomitant distal symmetric axonal polyneuropathy and CIDP. J Neurol 2002, 249:719722. Hughes RA: Systematic reviews of treatment for inflammatory demyelinating neuropathy. J Anat 2002, 200:331339.